After an expected resurrection, Celldex Therapeutics (CLDX) stock recovered and went as high as over $19 from less than $2 after an exaggerated selloff caused by investors following the failure to treat the still untreatable glioblastoma multiforme brain cancer.
Today Celldex announced that enrollment has opened, in its randomized, double-blind Phase 1b study of CDX-0159 in patients with . . .
This content is for paid subscribers.
Today’s Highlights October 13, 2020